Document Detail


Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease.
MedLine Citation:
PMID:  21389698     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND OBJECTIVES: Cardiovascular disease is prevalent in chronic kidney disease (CKD). Uric acid is increased in subjects with CKD and has been linked with cardiovascular mortality in this population. However, no study has evaluated the relationship of uric acid with angiographically proven coronary artery disease (CAD) in this population. We therefore investigated the link between serum uric acid (SUA) levels and (i) extent of CAD assessed by the Gensini score and (ii) inflammatory parameters, including C-reactive protein (CRP) and pentraxin-3, in patients with mild-to-moderate CKD.
MATERIAL AND METHODS: In an unselected population of 130 patients with estimated glomerular filtration rate (eGFR) between 90 and 30 ml/min/1.73 m(2), we measured SUA, serum pentraxin-3, CRP, urinary protein-to-creatinine ratio, lipid parameters and the severity of CAD as assessed by coronary angiography and quantified by the Gensini lesion severity score.
RESULTS: The mean serum values for SUA, pentraxin-3 and CRP in the entire study population were 5.5 ± 1.5 mg/dl, 6.4 ± 3.4 ng/ml and 3.5 ± 2.6 mg/dl, respectively. The Gensini scores significantly correlated in univariate analysis with gender (R = -0.379, p = 0.02), uric acid (R = 0.42, p = 0.001), pentraxin-3 (R = 0.54, p = 0.001), CRP (R = 0.29, p = 0.006) levels, eGFR (R = -0.33, p = 0.02), proteinuria (R = 0.21, p = 0.01), and presence of hypertension (R = 0.37, p = 0.001), but not with smoking status, diabetes mellitus, and lipid parameters. After adjustments for traditional cardiovascular risk factors, only uric acid (R = 0.21, p = 0.02) and pentraxin-3 (R = 0.28, p = 0.01) remained significant predictors of the Gensini score.
CONCLUSIONS: SUA and pentraxin-3 levels are independent determinants of severity of CAD in patients with mild-to-moderate CKD. We recommend a clinical trial to determine whether lowering uric acid could prevent progression of CAD in patients with CKD.
Authors:
Mehmet Kanbay; Mustafa Ikizek; Yalcin Solak; Yusuf Selcoki; Sema Uysal; Ferah Armutcu; Beyhan Eryonucu; Adrian Covic; Richard J Johnson
Related Documents :
1128168 - Positional analysis of isovaleroyl triglycerides using proton magnetic resonance with e...
1420948 - Effects of lipid structure on energy transfer from carbazolyl to anthryl groups in a li...
14737648 - Probing the stereochemistry of the active site of gamma-glutamyl transpeptidase using s...
17176098 - Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against h...
20492148 - Quality attributes and microbial storage stability of caviar from cultivated white stur...
4094928 - In vivo phototoxicity of non-steroidal anti-inflammatory drugs evaluated by the mouse t...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-03-10
Journal Detail:
Title:  American journal of nephrology     Volume:  33     ISSN:  1421-9670     ISO Abbreviation:  Am. J. Nephrol.     Publication Date:  2011  
Date Detail:
Created Date:  2011-04-28     Completed Date:  2011-08-29     Revised Date:  2012-04-10    
Medline Journal Info:
Nlm Unique ID:  8109361     Medline TA:  Am J Nephrol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  325-31     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Affiliation:
Division of Nephrology, Department of Medicine, Fatih University School of Medicine, Ankara, Turkey. drkanbay@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
C-Reactive Protein / biosynthesis*,  metabolism
Coronary Angiography / methods
Coronary Artery Disease / blood*,  complications*
Disease Progression
Female
Glomerular Filtration Rate
Humans
Inflammation
Kidney Diseases / blood*,  complications*
Male
Middle Aged
Risk Factors
Serum Amyloid P-Component / biosynthesis*
Uric Acid / metabolism*
Grant Support
ID/Acronym/Agency:
HL-68607/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Serum Amyloid P-Component; 148591-49-5/PTX3 protein; 69-93-2/Uric Acid; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Indoxyl Sulfate Downregulates Renal Expression of Klotho through Production of ROS and Activation of...
Next Document:  Historical background of bone conduction hearing devices and bone conduction hearing AIDS.